Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model

Urology

Volumn 68, Issue 3, 2006, Pages 674-681

  Wang, Hua ^a   Satoh, Makoto ^a   Abe, Hisashi ^a   Sunamura, Makoto ^a   Moriya, Takuya ^b   Ishidoya, Shigeto ^a   Saito, Seiichi ^a   Hamada, Hirofumi ^c   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DL 922947; E1A PROTEIN; E1B PROTEIN; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; URETER CANCER; VIRAL GENE THERAPY; VIRUS GENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADMINISTRATION, INTRAVESICAL; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 33748942284     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.04.021     Document Type: Article

References (22)

1. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guérin therapy for superficial bladder cancer: a 10-year followup. J Urol 147 (1992) 1020-1023
2. Fujimoto K., Yamada Y., Okajima E., et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52 (1992) 1393-1398
3. Sourvinos G., Kazanis I., Delakas D., et al. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J Urol 165 (2001) 249-252
4. Xu H.J., Cairns P., Hu S.X., et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53 (1993) 781-784
5. Heise C., Sampson-Johannes A., Williams A., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 (1997) 639-645
6. Fueyo J., Gomez-Manzano C., Alemany R., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19 (2000) 2-12
7. Heise C., Hermiston T., Johnson L., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6 (2000) 1134-1139
8. Harada J.N., and Berk A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73 (1999) 5333-5344
9. Fukuda K., Abei M., Ugai H., et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 63 (2003) 4434-4440
10. Markl I.D., and Jones P.A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 58 (1998) 5348-5353
11. Bean M.A., Pees H., and FOGH J.E. Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder: detection by a 3-H-proline microcytotoxicity test. Int J Cancer 14 (1974) 186-197
12. Kanegae Y., Lee G., Sato Y., et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 23 (1995) 3816-3821
13. Motoi F., Sunamura M., Ding L., et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 11 (2000) 223-235
14. Yoshida Y., and Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun 230 (1997) 426-430
15. Li Y., Pong R.-C., Bergelson J.M., et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59 (1999) 325-330
16. Ganly I., Kirn D., Eckhardt G., et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6 (2000) 798-806
17. Gomez-Manzano C., Balague C., Alemany R., et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23 (2004) 1821-1828
18. Wood M., Perrotte P., Onishi E., et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 6 (1999) 367-372
19. Horowitz J.M., Park S.H., Bogenmann E., et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87 (1990) 2775-2779
20. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
21. Rothmann T., Hengstermann A., Whitaker N.J., et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72 (1998) 9470-9478
22. Ries S.J., Brandts C.H., Chung A.S., et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6 (2000) 1128-1133